A Meta-Analysis of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
- Author:
Zhi-Hui TANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Glucagon-like peptide-1 receptor agonist; Meta-analysis; Nonalcoholic fatty liver disease; Systematic review; Type 2 diabetes mellitus
- From: Chinese Pharmaceutical Journal 2017;52(6):500-505
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To evaluate the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RA) on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). METHODS: The randomized controlled trials (RCTs) of GLP- 1 RA, placebo, and anti-diabetes drugs in the treatment of NAFLD in patients with T2DM were collected from PubMed, Embase, CNKI, Wangfang database, VIP, and CBM. The trials were evaluated for the quality and selected, and the results of the studies were reviewed and analyzed using RevMan 5.2 software. RESULTS: Four RCTs were included, involving 154 patients. The Meta-analysis showed that compared with the control group, GLP-1RA could significantly improve the ALT [MD: -8.36, 95% CI(-13.41-3.31), P = 0.001], HbA1c [MD: -0.43%, 95% CI(-0.73-0.31), P = 0.005], FBG [MD: -0.71%, 95% CI(-1. 39-0.03), P = 0.04], BMI [MD: -1.38%, 95% CI(-2.18-0.58), P = 0.000 8], TG [MD: -0.49%, 95% CI(-0.82-0.16), P = 0.004]. CONCLUSION: GLP-1 RA can obviously improve the metabolic index of patients with NAFLD and T2DM. Given the quality and quantity of the literature, large RCTs are still needed in the future.
